Clinical trials: Esophagogastric Junction
Siewert Type II Adenocarcinoma of Esophagogastric Junction
Comparison of Different Operations for Siewert Type II Adenocarcinoma of Esophagogastric Junction
The incidence of esophagogastric junction has been increasing in recent years, and surgery is an important method for the treatment of adenoma at the esophagogastric junction.
- Trial name
- NCT05356520
- Testing
- Endoscopy Ivor-lewis, Laparoscopic transabdominal enlarged gastrectomy
- Where
- China
- Volunteers
- 212 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Adenocarcinoma, Stomach Cancer
Prospective Evaluation of the Preoperative Lymph Node Staging in Patients With Cancer of the Esophagogastric Junction and Stomach
This prospective study includes patients with histologically proven cancer of the esophagogastric junction (Siewert Type II and III) and the stomach.
- Conditions
- Adenocarcinoma, Stomach Cancer, Cancer of Esophagogastric Junction
- Trial name
- NCT00800969
- Testing
- FDG-PET-CT
- Where
- Switzerland
- Sponsor
- University of Zurich
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction
RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00732745
- Testing
- docetaxel, oxaliplatin, vandetanib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Case Comprehensive Cancer Center
Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma
Perioperative Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gastric or GEJ Adenocarcinoma
The purpose of this clinical trial is to evaluate whether perioperative fruquintinib combined with sintilimab and SOX is effective in treating locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
- Trial name
- NCT07658872
- Testing
- fruquintinib + sintilimab + SOX, Sinitilimab+SOX
- Volunteers
- 120 people
- Sponsor
- Sichuan University
HER2-positive Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma
Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens
This trial is a single center, single arm, open label clinical study aimed at evaluating the efficacy and safety of the combination therapy of Disitamab Vedotin and trastuzumab in the treatment of advanced HER-2 positive…
- Trial name
- NCT06572319
- Testing
- Disitamab Vedotin(RC48) Plus Tratuzumab
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Zhejiang Cancer Hospital
Gastric Cancer
SOX Combined With Tislelizumab and LDRT for Neoadjuvant Treatment of Locally Advanced Gastric Cancer
Neoadjuvant chemotherapy or chemoradiotherapy has become the standard neoadjuvant regimen for locally advanced G/GEJ cancer and has been recommended by a series of treatment guidelines.
- Trial name
- NCT06266871
- Testing
- SOX+Tislelizumab+LDRT
- Volunteers
- 64 people
- Sponsor
- West China Hospital
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer
This phase 2 trial evaluates the benefit of epacadostat plus pembrolizumab in combination to treat patients with gastroesophageal junction or gastric cancer that has spread to other parts of the body and cannot be removed by…
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma
- Trial name
- NCT03196232
- Testing
- Epacadostat, Pembrolizumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- George Albert Fisher
Gastroesophageal Junction Adenocarcinoma
Efficacy and Safety of Neoadjuvant Chemoradiation Plus Serplulimab in Patients With Locally Advanced Adenocarcinoma of Gastroesophageal Junction
Investigators conduct the clinical trial to further explore the efficacy and safety of Neoadjuvant chemoradiation Plus Serpluimab in Patients with locally advanced Adenocarcinoma of Gastroesophageal Junction
- Trial name
- SNACRT (NCT05918419)
- Testing
- Serplulimab
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Peking Union Medical College Hospital
Gastric Cancer/Adenocarcinoma of Esophagogastric Junction
A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer
This is an open-label, single-arm, single-center clinical study to investigate the safety and efficacy of fuquinitinib combined with PD-1 inhibitors and first-line chemotherapy in the treatment of inoperable HER2-negative…
- Trial name
- G/GEJ cancer (NCT06158919)
- Testing
- Fruquintinib、Nivolumab、Sintilimab、Oxaliplatin、Teysuno、Capecitabine
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Fudan University
Gastric Cancer
Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer
The purpose of the trial is to compare the combination regimen of Telatinib and Capecitabine and Oxaliplatin vs. Capecitabine and Oxaplatin to explore superiority of the Telatinib combination in terms of progression-free survival…
- Trial name
- NCT03817411
- Testing
- Telatinib, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Taizhou EOC Pharma Co., Ltd.
Gastric Cancer, Gastroesophageal-junction Cancer
Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
The purpose of this study is to evaluate the efficacy of Tislelizumab in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ)…
- Trial name
- NCT05687357
- Testing
- Tislelizumab, S-1, Oxaliplatin
- Where
- 3 sites in China
- Volunteers
- 140 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Gastric Cancer, Gastroesophageal Junction Cancer
Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer
This study will evaluate overall survival of nimotuzumab in combination with irinotecan compared to irinotecan alone in subjects with EGFR overexpressed advanced gastric or gastroesophageal junction cancer.
- Trial name
- NCT01813253
- Testing
- Irinotecan, Nimotuzumab
- Where
- 37 sites in Japan, South Korea and 1 more
- Volunteers
- 400 people
- Sponsor
- Kuhnil Pharmaceutical Co., Ltd.
Gastric, or Gastroesophageal Junction Adenocarcinoma
Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
This study was designed to compare the efficacy and safety of tislelizumab plus chemotherapy versus placebo plus chemotherapy as the first treatment (first-line) for adults diagnosed with locally advanced unresectable or…
- Trial name
- NCT03777657
- Testing
- Tislelizumab, Cisplatin, Oxaliplatin
- Where
- 149 sites in United States, China and 11 more
- Volunteers
- 997 people
- Sponsor
- BeiGene
Gastric Cancer
Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
This is a randomized, controlled, multicenter phase Ⅲ study to evaluate the therapeutic efficacy of modified XELOX plus sintilimab versus standard XELOX plus sintilimab in subjects with advanced HER2-negative gastric or…
- Trial name
- NCT05918094
- Testing
- Experimental dose: modified XELOX + sintilimab, Standard dose: standard XELOX + sintilimab
- Where
- 10 sites in China
- Volunteers
- 540 people
- Sponsor
- Sun Yat-sen University
Esophageal Cancer, Gastric Cancer
Irinotecan in Treating Patients With Advanced Cancer of the Stomach
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have advanced…
- Trial name
- NCT00003137
- Testing
- irinotecan hydrochloride
- Where
- 19 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
This study is a prospective, open-label, phase II clinical trial that aims to enroll patients with locally advanced gastric adenocarcinoma who have not received any prior treatment and are candidates for surgery.
- Trial name
- NCT06385873
- Testing
- RC48, Adebrelimab, Apatinib
- Volunteers
- 32 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Advanced Malignancies, Metastatic Cancer
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
- Trial name
- NCT03277352
- Testing
- INCAGN01876, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Biosciences International Sàrl
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
ctDNA-MRD Monitoring After Neoadjuvant Therapy in Gastric Cancer With pCR or MPR
This prospective observational study will enroll adults with gastric or gastroesophageal junction adenocarcinoma who achieve pathological complete response or major pathological response after neoadjuvant therapy and R0…
- Trial name
- NCT07799649
- Testing
- Tumor-Informed ctDNA-MRD Monitoring, Clinician-Selected Standard-of-Care Postoperative Treatment
- Where
- China
- Volunteers
- 150 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
This trial is a Phase II study. All patients are resectable Gastric or Gastroesophageal Junction Adenocarcinoma, Eastern Cooperative Oncology Group (ECOG) performance status 0-1.The purpose of this study is to evaluate the…
- Trial name
- NCT05960955
- Testing
- Cadonilimab, AK117, Oxaliplatin
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Akeso
Obesity
Efficacy Evaluation of the Esophagogastric Junction Exposure Obtained by the Flexible Liver Retractor in Gastroplasty
Evaluation of a new technique of liver retraction for the exposure of the His angle in gastric bypass Roux-en-Y surgery.
- Trial name
- NCT02926885
- Testing
- CONVENTIONAL LIVER RETRACTOR DEVICE, FLEXIBLE LIVER RETRACTOR DEVICE, LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.